drugset / Trial / NCT00048360

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

NCT00048360

Phase 3 Completed 162 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).

Timeline

Start
2002-10
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 300 mg
Subject Bupropion Small molecule 450 mg